Defects DuringMecp2Null Embryonic Cortex Development Precede the Onset of Overt Neurological Symptoms-Reference-Cited by-同舟云学术

Defects DuringMecp2Null Embryonic Cortex Development Precede the Onset of Overt Neurological Symptoms

Published:2015-05-15 Issue:6 Volume:26 Page:2517-2529
ISSN:1047-3211
Container-title:Cerebral Cortex
language:en
Short-container-title:Cereb. Cortex

Author:

Bedogni Francesco,Cobolli Gigli Clementina,Pozzi Davide,Rossi Riccardo Lorenzo,Scaramuzza Linda,Rossetti Grazisa,Pagani Massimiliano,Kilstrup-Nielsen Charlotte,Matteoli Michela,Landsberger Nicoletta

Funder

Fondazione Cariplo

Fondazione Telethon

Jerome Lejeune Foundation

ERC Consolidator

Eurospin

Publisher

Oxford University Press (OUP)

Subject

Cellular and Molecular Neuroscience,Cognitive Neuroscience

Link

http://academic.oup.com/cercor/article-pdf/26/6/2517/17309796/bhv078.pdf

Reference87 articles.

1. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

2. The role of neuronal activity and transmitter release on synapse formation

3. Autoradiographic Study of Cell Migration during Histogenesis of Cerebral Cortex in the Mouse

4. Rett syndrome neuropathology review 2000

5. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study;Med;2024-09

2. Improvement in symptoms of Rett syndrome with trofinetide beyond clinical trial efficacy assessments: case reports;Future Rare Diseases;2024-07-15

3. Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model;Advances in Therapy;2024-07-04

4. Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study;Med;2024-07

5. MeCP2 gene therapy ameliorates disease phenotype in mouse model for Pitt Hopkins syndrome;Neurotherapeutics;2024-06